Lazari Capital Management Inc. Has $194,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

Lazari Capital Management Inc. cut its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 19.6% during the 2nd quarter, Holdings Channel reports. The fund owned 11,546 shares of the company’s stock after selling 2,809 shares during the period. Lazari Capital Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $194,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at about $39,000. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at about $43,000. Compagnie Lombard Odier SCmA acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $54,000. Banque Cantonale Vaudoise bought a new position in Teva Pharmaceutical Industries in the first quarter worth approximately $74,000. Finally, Brooklyn Investment Group grew its stake in Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock valued at $77,000 after acquiring an additional 4,014 shares during the period. 54.05% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

TEVA has been the topic of a number of research reports. UBS Group upped their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a “buy” rating and a $24.00 price target for the company. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and a consensus target price of $25.14.

Teva Pharmaceutical Industries Trading Down 0.3%

NYSE TEVA opened at $18.30 on Monday. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The business has a fifty day simple moving average of $17.77 and a 200 day simple moving average of $16.70. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The firm has a market capitalization of $20.99 billion, a P/E ratio of -114.38, a PEG ratio of 1.07 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business’s revenue for the quarter was up .3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.